Find Roflumilast manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

API REF. PRICE (USD/KG)

MARKET PLACE

FDF DossiersDRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 162401-32-3, Daxas, 3-(cyclopropylmethoxy)-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide, Daliresp, By217, Byk20869
Molecular Formula
C17H14Cl2F2N2O3
Molecular Weight
403.2  g/mol
InChI Key
MNDBXUUTURYVHR-UHFFFAOYSA-N
FDA UNII
0P6C6ZOP5U

Roflumilast
Roflumilast is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling. cAMP prevents phosphorylation of spleen tyrosine kinase (SYK) and abrogates activation of the PI3K/AKT/mTOR signaling pathway, which may result in the induction of apoptosis. PDE4, a member of the PDE superfamily that hydrolyses cAMP and 3',5'-cyclic guanosine monophosphate (cGMP) to their inactive 5' monophosphates, is upregulated in a variety of cancers and may contribute to chemoresistance; it also plays a key role in inflammation, especially in inflammatory airway diseases.
Roflumilast is a Phosphodiesterase 4 Inhibitor. The mechanism of action of roflumilast is as a Phosphodiesterase 4 Inhibitor.
1 2D Structure

Roflumilast

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
2.1.2 InChI
InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
2.1.3 InChI Key
MNDBXUUTURYVHR-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
2.2 Other Identifiers
2.2.1 UNII
0P6C6ZOP5U
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-di-chloropyrid-4-yl)benzamide

2. Daliresp

2.3.2 Depositor-Supplied Synonyms

1. 162401-32-3

2. Daxas

3. 3-(cyclopropylmethoxy)-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide

4. Daliresp

5. By217

6. Byk20869

7. By-217

8. B9302-107

9. By 217

10. 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide

11. Roflumilast (daxas)

12. Benzamide, 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-

13. Byk-20869

14. 0p6c6zop5u

15. Chembl193240

16. Chebi:47657

17. 3-cyclopropylmethoxy-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide

18. Byk 20869

19. Mfcd00938270

20. B 9302-107

21. Rof

22. Libertek

23. Roflumilast [usan]

24. B-9302-107

25. Roflumilast [usan:inn]

26. Unii-0p6c6zop5u

27. Roflumilastum

28. Roflumilast (jan/usan/inn)

29. Apta-2217

30. 1xmu

31. 1xoq

32. Daliresp (tn)

33. Roflumilast- Bio-x

34. 3g4l

35. Roflumilast [mi]

36. Roflumilast [inn]

37. Roflumilast [jan]

38. 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-di-chloropyrid-4-yl)benzamide

39. Roflumilast [vandf]

40. Roflumilast [mart.]

41. Schembl19158

42. Roflumilast [who-dd]

43. Mls006010074

44. Roflumilast [ema Epar]

45. Gtpl6962

46. Dtxsid8044123

47. Apta 2217

48. Bdbm14774

49. Roflumilast, >=98% (hplc)

50. Amy4219

51. Ex-a059

52. Roflumilast [orange Book]

53. Hms3655p21

54. Hms3748c19

55. Hms3884f09

56. Zinc592419

57. Act02619

58. Bcp03736

59. S2131

60. Arq-151/zoryve (roflumilast Cream)

61. Akos005146309

62. Am84550

63. Ccg-268678

64. Cs-0963

65. Db01656

66. Pb29130

67. Ncgc00346566-01

68. Ncgc00346566-09

69. Ac-23383

70. As-14120

71. Br164364

72. Hy-15455

73. Smr002530074

74. Sy008710

75. Bcp0726000146

76. Ft-0660846

77. R0193

78. Sw220196-1

79. A24672

80. D05744

81. Ab01565852_02

82. 401r323

83. Q693482

84. J-510858

85. Brd-k03194791-001-02-2

86. 3- Cyclo-propylmethoxy-4-difluoromethoxy-n- [3, 5-di-chloropyrid-4-yl]- Benzamid

87. Benzamide, 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-

88. N-(3,5-dichloropyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 403.2 g/mol
Molecular Formula C17H14Cl2F2N2O3
XLogP34.6
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count6
Rotatable Bond Count7
Exact Mass402.0349540 g/mol
Monoisotopic Mass402.0349540 g/mol
Topological Polar Surface Area60.4 Ų
Heavy Atom Count26
Formal Charge0
Complexity475
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameDaliresp
PubMed HealthRoflumilast (By mouth)
Drug ClassesRespiratory Agent
Drug LabelThe active ingredient in DALIRESP tablets is roflumilast. Roflumilast and its active metabolite (roflumilast N-oxide) are selective phosphodiesterase 4 (PDE4) inhibitors. The chemical name of roflumilast is N-(3,5-dichloropyridin-4-yl)-3-cyclopropylm...
Active IngredientRoflumilast
Dosage FormTablet
RouteOral
Strength500mcg
Market StatusPrescription
CompanyForest Res Inst

2 of 2  
Drug NameDaliresp
PubMed HealthRoflumilast (By mouth)
Drug ClassesRespiratory Agent
Drug LabelThe active ingredient in DALIRESP tablets is roflumilast. Roflumilast and its active metabolite (roflumilast N-oxide) are selective phosphodiesterase 4 (PDE4) inhibitors. The chemical name of roflumilast is N-(3,5-dichloropyridin-4-yl)-3-cyclopropylm...
Active IngredientRoflumilast
Dosage FormTablet
RouteOral
Strength500mcg
Market StatusPrescription
CompanyForest Res Inst

4.2 Drug Indication

Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm.


FDA Label


Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.


Libertek is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.


Daliresp is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.


Chronic obstructive pulmonary disease


5 Pharmacology and Biochemistry
5.1 Pharmacology

Roflumilast (and its active metabolite, roflumilast N-oxide) increases cyclic adenosine-3, 5-monophosphate (cAMP) in lung cells by inhibiting PDE4. Increased cAMP activates PKA, which inactivates transcription factors involved in inflammation. Romflumilast also decreases the amount of sputum neutrophils and eosinophils in COPD patients.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
ROFLUMILAST
5.2.2 FDA UNII
0P6C6ZOP5U
5.2.3 Pharmacological Classes
Phosphodiesterase 4 Inhibitors [MoA]; Phosphodiesterase 4 Inhibitor [EPC]
5.3 ATC Code

R03DX07


R03DX08


R03DX07


R03DX07

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


R - Respiratory system

R03 - Drugs for obstructive airway diseases

R03D - Other systemic drugs for obstructive airway diseases

R03DX - Other systemic drugs for obstructive airway diseases

R03DX07 - Roflumilast


5.4 Absorption, Distribution and Excretion

Absorption

After a 500mcg dose, the bioavailability of roflumilast is about 80%. In the fasted state, maximum plasma concentrations are reached in 0.5 to 2 hours. While in the fed state, Cmax is reduced by 40%, Tmax is increased by one hour, and total absorption is unchanged.


Route of Elimination

Roflumilast is excreted 70% in the urine as roflumilast N-oxide.


Volume of Distribution

Roflumilast has a Vd of 2.9L/kg with a dose of 500mcg. Permeability of roflumilast across the blood-brain barrier appears to be poor in rat studies.


Clearance

~9.6 L/hour.


5.5 Metabolism/Metabolites

Roflumilast is metabolized to roflumilast N-oxide, the active metabolite of roflumilast in humans, by CYP3A4 and CYP1A2.


5.6 Biological Half-Life

Plasma half-life of roflumilast is 17 hours and its metabolite is 30 hours (oral dose).


5.7 Mechanism of Action

Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor which, due to its selective inhibition of the PDE4 isoenzyme, has potential antiinflammatory and antimodulatory effects in the pulmonary system. It is thought that the increased levels of intracellular cyclic AMP are responsible for the therapeutic actions of Roflumilast.


USDMF

read-more
read-more

01

Interquim Sa

Spain
arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Flag Spain
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2015-01-05

Pay. Date : 2014-07-23

DMF Number : 28471

Submission : 2014-07-31

Status : Active

Type : II

Interquim

02

Veranova Lp

U.S.A
arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVeranova: A CDMO that manages complexity with confidence.

Flag U.S.A
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2018-02-28

Pay. Date : 2017-09-25

DMF Number : 32093

Submission : 2017-10-31

Status : Active

Type : II

Veranova

03

Antibody Engineering
Not Confirmed

04

Antibody Engineering
Not Confirmed

04

Antibody Engineering
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-06-29

Pay. Date : 2018-06-04

DMF Number : 32851

Submission : 2018-06-01

Status : Active

Type : II

blank

05

Antibody Engineering
Not Confirmed

05

Antibody Engineering
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-01-21

Pay. Date : 2014-09-10

DMF Number : 28506

Submission : 2014-07-22

Status : Active

Type : II

blank

06

Hetero Drugs Ltd

India

USDMF

arrow
Antibody Engineering
Not Confirmed

06

Antibody Engineering
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2014-11-17

Pay. Date : 2014-08-14

DMF Number : 28516

Submission : 2014-08-27

Status : Active

Type : II

blank

07

Antibody Engineering
Not Confirmed

07

Antibody Engineering
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2014-08-27

Pay. Date : 2014-07-03

DMF Number : 27612

Submission : 2013-11-30

Status : Active

Type : II

blank

08

Scinopharm Taiwan Ltd

Taiwan

USDMF

arrow
Antibody Engineering
Not Confirmed

08

Antibody Engineering
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2014-09-08

Pay. Date : 2014-03-13

DMF Number : 26764

Submission : 2012-12-27

Status : Active

Type : II

blank

09

Antibody Engineering
Not Confirmed

09

Antibody Engineering
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-04-21

Pay. Date : 2021-03-04

DMF Number : 35661

Submission : 2021-03-11

Status : Active

Type : II

blank

10

Antibody Engineering
Not Confirmed

10

Antibody Engineering
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2014-11-11

Pay. Date : 2014-08-04

DMF Number : 28440

Submission : 2014-09-04

Status : Active

Type : II

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-more

01

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Roflumilast IH

Date of Issue : 2022-06-06

Valid Till : 2025-06-10

Written Confirmation Number : WC-0017

Address of the Firm : Unit No. VIII, Sy. No. 10 & 13, Gaddapotharam Village, I,D.A. Kazipally, Jinnara...

blank

02

Hetero Drugs

India
Antibody Engineering
Not Confirmed
arrow

Hetero Drugs

India
arrow
Antibody Engineering
Not Confirmed

Roflumilast IH

Date of Issue : 2022-07-04

Valid Till : 2025-07-03

Written Confirmation Number : WC-0040

Address of the Firm : Unit-I, Survey No.213, 214 & 255,  Bonthapally Village, Jinnaram Mandal, Medak ...

blank

03

Hetero Drugs

India
Antibody Engineering
Not Confirmed
arrow

Hetero Drugs

India
arrow
Antibody Engineering
Not Confirmed

Roflumilast IH

Date of Issue : 2022-02-25

Valid Till : 2022-07-03

Written Confirmation Number : WC-0040A3

Address of the Firm : Unit-I, Survey No.213, 214 & 255, Bonthapally Village, Jinnaram Mandal, Medak D...

blank

04

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Roflumilast IH

Date of Issue : 2022-06-17

Valid Till : 2025-07-14

Written Confirmation Number : WC-0021n

Address of the Firm : Sy. Nos: 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Man...

blank

05

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Roflumilast (IH)

Date of Issue : 2019-07-15

Valid Till : 2022-07-14

Written Confirmation Number : WC-0021

Address of the Firm : Sy. No.317&323, Rudraram Village, Patancheru Mandal, Sangaredy District-502329 T...

blank

06

Viatris

U.S.A
Antibody Engineering
Not Confirmed
arrow

Viatris

U.S.A
arrow
Antibody Engineering
Not Confirmed

Roflumilast IH

Date of Issue : 2019-10-11

Valid Till : 2022-07-02

Written Confirmation Number : WC-0157

Address of the Firm : Plot No. 1A/2, MIDC, Taloja, Panvel, Dist. Raigad, Maharashtra State

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-more

01

Interquim SA

Spain
arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Flag Spain
Digital Content Digital Content

Roflumilast

Registrant Name : Seongi Bio Co., Ltd.

Registration Date : 2016-12-29

Registration Number : Su259-4-ND

Manufacturer Name : Interquim, SA

Manufacturer Address : Joan Buscalla 10, E-08173 Sant Cugat del Valles, Barcelona, ​​Spain

Interquim

02

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Roflumilast

Registrant Name : Pharmapia Co., Ltd.

Registration Date : 2017-04-03

Registration Number : Su258-2-ND

Manufacturer Name : MSN Laboratories Private Lim...

Manufacturer Address : Sy. No. 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Mandal), ...

blank

03

Siegfried AG

Switzerland
Antibody Engineering
Not Confirmed
arrow

Siegfried AG

Switzerland
arrow
Antibody Engineering
Not Confirmed

Roflumilast

Registrant Name : AstraZeneca Korea Ltd.

Registration Date : 2014-09-17

Registration Number : Su5550-4-ND

Manufacturer Name : Siegfried Evionnaz SA_x000D_...

Manufacturer Address : Route du Simplon 1, 36, 1902 Evionnaz, Switzerland_x000D_ @[Pulverization Process] Vi...

blank

04

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Roflumilast

Registrant Name : AstraZeneca Korea Ltd.

Registration Date : 2011-04-29

Registration Number : Su5550-1-ND

Manufacturer Name : Takeda GmbH, Production site...

Manufacturer Address : Robert-Bosch-Strass 8 78224 Singen Germany

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Flag Spain
Digital Content Digital Content

ROFLUMILAST

NDC Package Code : 64552-4096

Start Marketing Date : 2011-02-28

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Interquim

02

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Flag Spain
Digital Content Digital Content

ROFLUMILAST

NDC Package Code : 64552-4067

Start Marketing Date : 2011-02-28

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Interquim

03

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Flag Spain
Digital Content Digital Content

ROFLUMILAST

NDC Package Code : 64552-4053

Start Marketing Date : 2011-02-28

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Interquim

04

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

NDC Package Code : 59651-222

Start Marketing Date : 2023-12-07

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (50kg/50kg)

Marketing Category : BULK INGREDIENT

blank

05

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

NDC Package Code : 65977-0111

Start Marketing Date : 2011-02-28

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

NDC Package Code : 14501-0078

Start Marketing Date : 2012-03-22

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

07

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

NDC Package Code : 54245-7016

Start Marketing Date : 2013-12-02

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

NDC Package Code : 61730-0010

Start Marketing Date : 2023-12-06

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

09

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

NDC Package Code : 65015-850

Start Marketing Date : 2015-02-20

End Marketing Date : 2026-12-01

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

10

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

NDC Package Code : 82245-0118

Start Marketing Date : 2018-01-23

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Interquim SA

Spain
arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Flag Spain
Digital Content Digital Content

Roflumilast

About the Company : Interquim, founded in 1978, is now part of the Ferrer HealthTech division. Interquim specializes in the development of competitive processes for manufacturing high added-value APIs...

Interquim, founded in 1978, is now part of the Ferrer HealthTech division. Interquim specializes in the development of competitive processes for manufacturing high added-value APIs that meet stringent quality standards. Complying with European environmental and work safety regulations, Interquim’s products are exported to highly regulated pharmaceutical markets. Regulatory bodies and clients have approved its quality system and facilities. With state-of-the-art multi-production plants, drug synthesis, and quality-control labs, Interquim supports clients throughout the entire product lifecycle, from product development to marketing.
Interquim

02

M2i Group

France
arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothM2i Group, an integrated CDMO, is your French partner for development & manufacturing in fine chemistry.

Flag France
Digital Content Digital Content

Roflumilast

About the Company : Integrated solutions for all your projects.
M2i Group provides integrated solutions for all your projects. We offer our clients an integrated partner, from early development...

Integrated solutions for all your projects. M2i Group provides integrated solutions for all your projects. We offer our clients an integrated partner, from early development to commercial supply of high-value niche fine chemicals for the pharmaceutical and biocontrol industry. Our offerings include: - Proprietary molecule portfolio: API, synthesis intermediates, key building blocks & pheromones - Custom development & manufacturing: Process development, industrialization & production - Contract Research: Outsourced research services - Consulting/accompaniment: R&D, innovation, key sourcing & industrial strategy
m2i group

03

LGM Pharma

U.S.A
arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Roflumilast

About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.
LGM Pharma CB

04

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content

Roflumilast

About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...

HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It offers services such as sourcing, manufacturing & supply, helping partners enter new markets worldwide. Its strong partnerships with major players in the pharma and food additive industries help HRV Global effectively promote projects and products. HRV Global represents over 30 large Indian drugmakers, primarily targeting Europe, the US & the Middle East markets. Headquartered in India, HRV Global has offices in the US, Switzerland, Dubai, Lithuania & Turkey.
HRV Global Life Sciences

05

CHEMO

Spain
Antibody Engineering
Not Confirmed
arrow

CHEMO

Spain
arrow
Antibody Engineering
Not Confirmed

Roflumilast

About the Company : More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, ...

More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, and starts business activities trading with pharmaceutical raw materials. In the 80's, the company expanded its operations into the Industrial Business, developing and manufacturing active pharmaceutical ingredients (APIs) in Italy (Industriale Chimica) and in Spain (Quimica Sintetica). In the 90's, CHEMO starts developing and manufacturing high quality and technology finished dosage forms (FDFs).
blank

06

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Roflumilast

About the Company : Chongqing Huapont Pharmaceutical Co., Ltd. was established in 1994 and is now located in Liangjiang New District, Chongqing. It is a national high-tech enterprise, a national innov...

Chongqing Huapont Pharmaceutical Co., Ltd. was established in 1994 and is now located in Liangjiang New District, Chongqing. It is a national high-tech enterprise, a national innovative enterprise, and a national demonstration enterprise for a new model of intelligent manufacturing. It has a national enterprise technology center and multiple municipal R&D platforms, two formulation factories, and two API factories. In addition, the company is also widely involved in the fields of respiratory, cardiovascular and cerebrovascular, blood, tumor, and systemic hormones, and has accumulated a large number of blockbuster drugs.
blank

07

DEAFARMA

Italy
Antibody Engineering
Not Confirmed
arrow

DEAFARMA

Italy
arrow
Antibody Engineering
Not Confirmed

Roflumilast

About the Company : In the dinamic pharmaceutical field, DEAFARMA is the reference point for primaries Pharmaceutical Laboratories for over twenty years, even in the national and international territo...

In the dinamic pharmaceutical field, DEAFARMA is the reference point for primaries Pharmaceutical Laboratories for over twenty years, even in the national and international territory. DEAFARMA works with success in the pharmaceutical raw materials field through Agencies and professional relations with the most important European and Asiatic factories. Our partners are well known, reliable producers and all of them are operating in accordance with the latest GMP Rules. The APIs mentioned in the DEAFARMA catalogue are always supported by DMF and/or CEP.
blank

08

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Roflumilast

About the Company : Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in mark...

Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in markets across emerging economies including India. The generics business services the requirements of developed markets like US and Western Europe. Our API business sells products in over 65 countries including the US, various countries in the EU, South America and India. With 15 manufacturing facilities and 3 R&D centers dedicated to the goal of enriching lives across the globe.
blank

09

Hetero Drugs

India
Antibody Engineering
Not Confirmed
arrow

Hetero Drugs

India
arrow
Antibody Engineering
Not Confirmed

Roflumilast

About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs. Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization.
blank

10

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Roflumilast

About the Company : Hunan Huateng Pharmaceutical Co., Ltd. is a research-based manufacturer and supplier of combinatorial building blocks, organics and fine chemicals, with 5000m2 laboratory and over ...

Hunan Huateng Pharmaceutical Co., Ltd. is a research-based manufacturer and supplier of combinatorial building blocks, organics and fine chemicals, with 5000m2 laboratory and over 100 experienced chemists. Huateng is dedicated to bring high quality and cost effective chemical products and services to our clients. Our versatile chemical synthesis expertise and manufacturing capability prepare us to produce a variety of known, novel or even hard-to-find chemicals from kg to ton scale.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"ROFLUMILAST","year":"2021","qtr":"Q1","strtotime":1610044200,"product":"ROFLUMILAST IH","address":"HETERO HOUSE, H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD-A.P.","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"PERRIGO COMPANY PLC","customerCountry":"ISRAEL","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"180321.4","totalValueFC":"1825.7","currency":"USD","unitRateINR":13352800,"date":"08-Jan-2021","totalValueINR":"133528","totalValueInUsd":"1825.7","indian_port":"HYDERABAD AIR","hs_no":"29333911","bill_no":"7764282","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE, H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD-A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"ROFLUMILAST","year":"2021","qtr":"Q2","strtotime":1618943400,"product":"ROFLUMILAST (GROUP:B SR NO:8119) (TAX IN","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"MONTREAL","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"CANADA","quantity":"0.11","actualQuantity":"0.105","unit":"KGS","unitRateFc":"200000","totalValueFC":"20873.3","currency":"USD","unitRateINR":14800000,"date":"21-Apr-2021","totalValueINR":"1554000","totalValueInUsd":"20873.3","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"1257100","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1622485800,"product":"ROFLUMILAST (TAX INVOICE NO:1900215171 DT:24-05-2021) (GROUP:A","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"PERRIGO COMPANY PLC","customerCountry":"ISRAEL","quantity":"0.01","actualQuantity":"0.007","unit":"KGS","unitRateFc":"251040.9","totalValueFC":"1721.6","currency":"USD","unitRateINR":18087500,"date":"01-Jun-2021","totalValueINR":"126612.5","totalValueInUsd":"1721.6","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"2146621","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1637519400,"product":"ROFLUMILAST (TAX INVOICE NO:1900215903","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"CANADA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"200000","totalValueFC":"58908.6","currency":"USD","unitRateINR":14623333.333333334,"date":"22-Nov-2021","totalValueINR":"4387000","totalValueInUsd":"58908.6","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"6169958","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648233000,"product":"339977 - ROFLUMILAST - NN4297","address":"SITE NO.1,BOMMASANDRA INDL.AREA,IV ,PHASE,JIGANI LINK ROAD ANEKAL TALU","city":"BANGALORE,KARNATAKA","supplier":"APOTEX INC","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"ADLI LOGISTICS","customerCountry":"CANADA","quantity":"0.16","actualQuantity":"0.159","unit":"KGS","unitRateFc":"79078.1","totalValueFC":"12411.5","currency":"USD","unitRateINR":5949685.5345911952,"date":"26-Mar-2022","totalValueINR":"946000","totalValueInUsd":"12411.5","indian_port":"BANGALORE ICD","hs_no":"29331999","bill_no":"9222536","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE ICD","supplierAddress":"SITE NO.1,BOMMASANDRA INDL.AREA,IV ,PHASE,JIGANI LINK ROAD ANEKAL TALU, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1656873000,"product":"ROFLUMILAST","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SHANGHAI","customer":"TO THE ORDER OF","customerCountry":"CHINA","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"225000","totalValueFC":"327101.8","currency":"USD","unitRateINR":17340000,"date":"04-Jul-2022","totalValueINR":"26010000","totalValueInUsd":"327101.8","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"2594140","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691087400,"product":"CS-O-11739 \/ ROFLUMILAST","address":"NA","city":"MUMBAI","supplier":"CLEARSYNTH LABS LIMITED","supplierCountry":"INDIA","foreign_port":"HO CHI MINH CITY","customer":"NAVIS VIETNAM CO LIMITED","customerCountry":"VIETNAM","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"240","totalValueFC":"236.6","currency":"USD","unitRateINR":19600.308000000001,"date":"04-Aug-2023","totalValueINR":"19600.308","totalValueInUsd":"236.6","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"VIETNAM","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"NA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696617000,"product":"ROFLUMILAST","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"TO THE ORDER OF,....;;","customerCountry":"CANADA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"100000","totalValueFC":"98679.2","currency":"USD","unitRateINR":8213000,"date":"07-Oct-2023","totalValueINR":"8213000","totalValueInUsd":"98679.2","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4469065","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697567400,"product":"ROFLUMILAST RC B(NET WT: 500 GM X 1 VIAL) (PRODUCT VALVE= 1.85 USD X 500 MG = 925 USD)","address":"PLOT NO. 2, SY NO.110,","city":"SECUNDERABAD, TELANGANA.","supplier":"VENKATASAI LIFE SCIENCES","supplierCountry":"INDIA","foreign_port":"HAIFA","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"ISRAEL","quantity":"0.00","actualQuantity":"0.5","unit":"GMS","unitRateFc":"1890","totalValueFC":"913.1","currency":"USD","unitRateINR":152000,"date":"18-Oct-2023","totalValueINR":"76000","totalValueInUsd":"913.1","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4732045","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. 2, SY NO.110,, SECUNDERABAD, TELANGANA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715711400,"product":"ROFLUMILAST","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"FARMATRADE SRL","customerCountry":"ARGENTINA","quantity":"0.01","actualQuantity":"10","unit":"GMS","unitRateFc":"85","totalValueFC":"802.7","currency":"USD","unitRateINR":6690.6000000000004,"date":"15-May-2024","totalValueINR":"66906","totalValueInUsd":"802.7","indian_port":"Ahmedabad Air","hs_no":"29333929","bill_no":"9878873","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719167400,"product":"ROFLUMILAST USP (AS PER INV)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NEWARK, NJ","customer":"MSN PHARMACEUTICALS INC","customerCountry":"UNITED STATES","quantity":"0.80","actualQuantity":"0.8","unit":"KGS","unitRateFc":"153915","totalValueFC":"121712.2","currency":"USD","unitRateINR":12700582.987500001,"date":"24-Jun-2024","totalValueINR":"10160466.39","totalValueInUsd":"121712.2","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"1896941","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720636200,"product":"ROFLUMILAST","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"PHARMAPIA CO. LTD","customerCountry":"REPUBLIC OF KOREA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"180000","totalValueFC":"53343.7","currency":"USD","unitRateINR":14863526.666666668,"date":"11-Jul-2024","totalValueINR":"4459058","totalValueInUsd":"53343.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"2344233","productDescription":"API","marketType":"REGULATED MARKET","country":"REPUBLIC OF KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720722600,"product":"ROFLUMILAST USP","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SHANGHAI - PU DONG","customer":"ZHEJIANG HUAHAI PHARMA CO., LTD","customerCountry":"CHINA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"215000","totalValueFC":"212588.9","currency":"USD","unitRateINR":17770534.289999999,"date":"12-Jul-2024","totalValueINR":"17770534.29","totalValueInUsd":"212588.9","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"2379334","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721241000,"product":"ROFLUMILAST USP","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NEWARK, NJ","customer":"MSN PHARMACEUTICALS INC.","customerCountry":"UNITED STATES","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"153915","totalValueFC":"30324.7","currency":"USD","unitRateINR":12674360.5,"date":"18-Jul-2024","totalValueINR":"2534872.1","totalValueInUsd":"30324.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"2504680","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
08-Jan-2021
18-Jul-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

INTERMEDIATES SUPPLIERS

read-more
read-more

01

M2i Group

France
Antibody Engineering
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothM2i Group, an integrated CDMO, is your French partner for development & manufacturing in fine chemistry.

CAS Number : 7051-34-5

End Use API : Roflumilast

About The Company : Integrated solutions for all your projects.
M2i Group provides integrated solutions for all your projects. We offer our clients an integrated partner, fr...

m2i group

02

Minakem

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMinakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

CAS Number : 5911-08-0

End Use API : Roflumilast

About The Company : MINAKEM is a cGMP custom manufacturer of small molecule API, HPAPI and steroids. All development and manufacturing activities are supported by highly skilled R&...

Minakem Comapny Banner

03

Minakem

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMinakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

CAS Number : 7051-34-5

End Use API : Roflumilast

About The Company : MINAKEM is a cGMP custom manufacturer of small molecule API, HPAPI and steroids. All development and manufacturing activities are supported by highly skilled R&...

Minakem Comapny Banner

04

Antibody Engineering
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFaran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.

CAS Number : 7051-34-5

End Use API : Roflumilast

About The Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutica...

Faran Shimi Pharmaceutical

05

LinkChem

China
Antibody Engineering
Not Confirmed
arrow

LinkChem

China
Antibody Engineering
Not Confirmed
arrow

CAS Number : 1159429-52-3

End Use API : Roflumilast

About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

blank

06

Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed
arrow

CAS Number : 139-85-5

End Use API : Roflumilast

About The Company : V & V Pharma Industries is a Manufacturer & Exporter of Active Pharmaceutical Ingredients (API's), Pharmaceutical Intermediates & Specialty Chemicals. V & V Pha...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

BRECKENRIDGE

U.S.A
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

Brand Name : ROFLUMILAST

Dosage Form : TABLET;ORAL

Dosage Strength : 500MCG

Approval Date : 2018-10-03

Application Number : 208236

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

Breckenridge Pharmaceutical

02

BRECKENRIDGE

U.S.A
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

Brand Name : ROFLUMILAST

Dosage Form : TABLET;ORAL

Dosage Strength : 250MCG

Approval Date : 2023-10-19

Application Number : 208236

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

Breckenridge Pharmaceutical

03

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

Flag India
Digital Content Digital Content

RLD : No

TE Code : AB

ROFLUMILAST

Brand Name : ROFLUMILAST

Dosage Form : TABLET;ORAL

Dosage Strength : 500MCG

Approval Date : 2020-03-30

Application Number : 208247

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

Strides Pharma Science

04

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

Flag India
Digital Content Digital Content

RLD : No

TE Code : AB

ROFLUMILAST

Brand Name : ROFLUMILAST

Dosage Form : TABLET;ORAL

Dosage Strength : 250MCG

Approval Date : 2023-06-20

Application Number : 208247

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

Strides Pharma Science

05

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

Brand Name : ROFLUMILAST

Dosage Form : TABLET;ORAL

Dosage Strength : 250MCG

Approval Date : 2023-04-18

Application Number : 212490

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

06

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

Brand Name : ROFLUMILAST

Dosage Form : TABLET;ORAL

Dosage Strength : 500MCG

Approval Date : 2023-04-18

Application Number : 212490

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

07

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

Brand Name : ROFLUMILAST

Dosage Form : TABLET;ORAL

Dosage Strength : 500MCG

Approval Date : 2018-11-23

Application Number : 208213

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

08

MICRO LABS

India
Antibody Engineering
Not Confirmed
arrow

MICRO LABS

India
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

Brand Name : ROFLUMILAST

Dosage Form : TABLET;ORAL

Dosage Strength : 500MCG

Approval Date : 2019-03-22

Application Number : 208180

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

09

MICRO LABS

India
Antibody Engineering
Not Confirmed
arrow

MICRO LABS

India
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

Brand Name : ROFLUMILAST

Dosage Form : TABLET;ORAL

Dosage Strength : 250MCG

Approval Date : 2023-04-18

Application Number : 208180

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

10

ZYDUS PHARMS

U.S.A
Antibody Engineering
Not Confirmed
arrow

ZYDUS PHARMS

U.S.A
arrow
Antibody Engineering
Not Confirmed

ROFLUMILAST

Brand Name : ROFLUMILAST

Dosage Form : TABLET;ORAL

Dosage Strength : 500MCG

Approval Date : 2022-02-10

Application Number : 208303

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Roflumilast

Brand Name : Quadruple

Dosage Form : Tablet, film-coated

Dosage Strength : 500 micrograms

Packaging : Blisterpakning 30item

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

02

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Roflumilast

Brand Name : Quadruple

Dosage Form : Tablet, film-coated

Dosage Strength : 500 micrograms

Packaging : Blisterpakning 90item

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

03

AstraZeneca AB (2)

United Kingdom
Antibody Engineering
Not Confirmed
arrow

AstraZeneca AB (2)

United Kingdom
arrow
Antibody Engineering
Not Confirmed

Roflumilast

Brand Name : Daxas

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 500 mcg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

04

AstraZeneca AB (2)

United Kingdom
Antibody Engineering
Not Confirmed
arrow

AstraZeneca AB (2)

United Kingdom
arrow
Antibody Engineering
Not Confirmed

Roflumilast

Brand Name : Daxas

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 500 mcg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

05

AstraZeneca AG

United Kingdom
Antibody Engineering
Not Confirmed
arrow

AstraZeneca AG

United Kingdom
arrow
Antibody Engineering
Not Confirmed

Roflumilastum

Brand Name : Daxas

Dosage Form : Filmtabl

Dosage Strength : 500mcg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

06

Orifarm AS

Denmark
Antibody Engineering
Not Confirmed
arrow

Orifarm AS

Denmark
arrow
Antibody Engineering
Not Confirmed

Roflumilast

Brand Name : Daxas

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 500 mcg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

07

Takeda GmbH

Japan
Antibody Engineering
Not Confirmed
arrow

Takeda GmbH

Japan
arrow
Antibody Engineering
Not Confirmed

roflumilast

Brand Name : Daxas

Dosage Form : FILM COATED PILL

Dosage Strength : 500 MICROGRAMS

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

08

Takeda GmbH

Japan
Antibody Engineering
Not Confirmed
arrow

Takeda GmbH

Japan
arrow
Antibody Engineering
Not Confirmed

roflumilast

Brand Name : Libertek

Dosage Form : FILM COATED PILL

Dosage Strength : 500 MICROGRAMS

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

09

TAKEDA GMBH

Japan
Antibody Engineering
Not Confirmed
arrow

TAKEDA GMBH

Japan
arrow
Antibody Engineering
Not Confirmed

Roflumilast

Brand Name : Daxas

Dosage Form : Roflumilast 500Mcg 30 Joined' Oral Use

Dosage Strength : 30 cpr riv 500 mcg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

10

Country
Antibody Engineering
Not Confirmed
arrow

Country
arrow
Antibody Engineering
Not Confirmed

Roflumilast

Brand Name : 30 Libertek 500Mcg Film-Coated Tablets

Dosage Form : Film Coated Tablet

Dosage Strength : 500 Mcg/Film Coated Tablet

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - TABLET;ORAL - 250MCG

USFDA APPLICATION NUMBER - 22522

read-more

DOSAGE - TABLET;ORAL - 500MCG

USFDA APPLICATION NUMBER - 22522

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Granulation

read-more
read-more

Co-Processed Excipients

read-more
read-more

Lubricants & Glidants

read-more
read-more

Solubilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Controlled & Modified Release

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Taste Masking

read-more
read-more

Parenteral

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Coating Systems & Additives

read-more
read-more

Emulsifying Agents

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty